Agios Pharmaceuticals (AGIO) Net Income towards Common Stockholders (2012 - 2026)
Agios Pharmaceuticals (AGIO) posted Net Income towards Common Stockholders of -$147.8 million for Q1 2026, down 36.76% on a QoQ basis from -$108.0 million in Q4 2025, and down 32.56% year-over-year from -$219.1 million in Q1 2025.
Agios Pharmaceuticals (AGIO) Net Income towards Common Stockholders (2012 - 2026) Analysis & Trends
Agios Pharmaceuticals' Net Income towards Common Stockholders history runs 14 years deep, the most recent figure standing at -$147.8 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 32.56% year-over-year to -$147.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$491.2 million (down 178.04% YoY) and the FY2025 annual result came in at -$412.8 million, down 161.27% from the prior year.
- Net Income towards Common Stockholders was -$147.8 million for Q1 2026 at Agios Pharmaceuticals, down from -$108.0 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $947.9 million in Q3 2024 and bottomed at -$147.8 million in Q1 2026.
- A 4-year average of -$24.8 million and a median of -$96.7 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders jumped 1137.97% — and 2025, when it plunged 110.91%.
- Agios Pharmaceuticals' Net Income towards Common Stockholders stood at -$95.9 million in 2023, then slipped by 0.61% to -$96.5 million in 2024, then fell by 11.93% to -$108.0 million in 2025, then plunged by 36.76% to -$147.8 million in 2026.
- Business Quant data shows AGIO's Net Income towards Common Stockholders at -$147.8 million in Q1 2026, -$108.0 million in Q4 2025, and -$103.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Agios Pharmaceuticals | 2.20 Bn | 1.46 Bn | 19.43 Mn | -147.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -147.76 Mn |
| Dec 31, 2025 | -108.04 Mn |
| Sep 30, 2025 | -103.43 Mn |
| Jun 30, 2025 | -131.97 Mn |
| Mar 31, 2025 | -111.47 Mn |
| Dec 31, 2024 | -96.52 Mn |
| Sep 30, 2024 | 947.92 Mn |
| Jun 30, 2024 | -110.50 Mn |
| Mar 31, 2024 | -96.73 Mn |
| Dec 31, 2023 | -95.94 Mn |
| Sep 30, 2023 | -91.32 Mn |
| Jun 30, 2023 | -89.99 Mn |
| Mar 31, 2023 | -87.04 Mn |
| Dec 31, 2021 | 3.96 Mn |
| Sep 30, 2021 | -4.51 Mn |
| Jun 30, 2021 | -3.43 Mn |
| Mar 31, 2021 | 1.97 Bn |
| Dec 31, 2020 | -13.12 Mn |
| Sep 30, 2020 | -19.80 Mn |
| Jun 30, 2020 | -8.98 Mn |